Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP6V1B1 | P15313 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239741 | 1.00 | ATP6V1B1 (0.51) | ATP6V1B1PDGFRBPDGFRACYP2A6ALOX5 | |
| SCHEMBL12809345 | 0.84 | ATP6V1B1 (0.61) | ATP6V1B1PDGFRBPDGFRACYP2A6MAPT | |
| SCHEMBL5313959 | 0.84 | ATP6V1B1 (0.61) | ATP6V1B1PDGFRBPDGFRACYP2A6MAPT | |
| SCHEMBL24601171 | 0.83 | CYP2A6 (0.44) | PDGFRBPDGFRACYP2A6MAPTTTR | |
| SCHEMBL951355 | 0.82 | ALDH1A1 (0.59) | PDGFRBPDGFRAMAPTCYP1A2KDM4E | |
| SCHEMBL951357 | 0.82 | ALDH1A1 (0.59) | PDGFRBPDGFRAMAPTCYP1A2KDM4E | |
| SCHEMBL22074483 | 0.82 | NPC1 (0.50) | PDGFRBPDGFRAMAPTCYP1A2CYP2D6 | |
| SCHEMBL14386994 | 0.81 | CYP2A6 (0.51) | ATP6V1B1PDGFRBPDGFRACYP2A6MAPT | |
| SCHEMBL5360579 | 0.81 | ATP6V1B1 (0.51) | ATP6V1B1PDGFRBPDGFRACYP2A6MAPT | |
| SCHEMBL5360581 | 0.81 | ATP6V1B1 (0.51) | ATP6V1B1PDGFRBPDGFRACYP2A6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3290419-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| EP-3312179-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2019-07-10 | — | — | EP | disclosed |
| US-20180354953-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-12-13 | — | — | US | disclosed |
| US-10093656-B2 | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor | NANJING SANHOME PHARMACEUTICAL CO., LTD (CN) | 2018-10-09 | — | — | US | disclosed |
| EP-3312179-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-25 | — | — | EP | disclosed |
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-15 | — | — | US | disclosed |
| EP-3290419-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-07 | — | — | EP | disclosed |
| EP-2697223-B1 | 7-(HETEROARYL-AMINO)-6,7,8,9-TETRAHYDROPYRIDO[1,2-A]INDOL ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-9096595-B2 | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD (CH) | 2015-08-04 | — | — | US | disclosed |
| EP-2697223-A1 | 7-(HETEROARYL-AMINO)-6,7,8,9-TETRAHYDROPYRIDO[1,2-A]INDOL ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2014-02-19 | — | — | EP | disclosed |
| US-20140045870-A1 | 7-(Heteroaryl-Amino)-6,7,8,9-Tetrahydropyrido[1,2-A]Indol Acetic Acid Derivatives and Their Use as Prostaglandin D2 Receptor Modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-02-13 | — | — | US | disclosed |
| WO-2012140612-A1 | 7-(HETEROARYL-AMINO)-6,7,8,9-TETRAHYDROPYRIDO[1,2-A]INDOL ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-10-18 | — | — | WO | disclosed |
| US-20110201641-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | EGFR, ERBB2, ERBB4 | ATP6V1B1 2123/4885PDGFRB 27/4885PDGFRA 33/4885 |
| US-20140045870-A1 | 7-(Heteroaryl-Amino)-6,7,8,9-Tetrahydropyrido[1,2-A]Indol Acetic Acid Derivatives and Their Use as Prostaglandin D2 Receptor Modulators | PTGDR, PTGDR2, PTGER1 | ATP6V1B1 1451/4885PDGFRB 648/4885PDGFRA 401/4885 |
| US-10093656-B2 | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor | EGFR, ERBB2, ERBB4 | ATP6V1B1 2123/4885PDGFRB 27/4885PDGFRA 33/4885 |
| US-20110201641-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | HRH2, MTNR1B, MTNR1A | ATP6V1B1 3492/4885PDGFRB 1785/4885PDGFRA 2170/4885 |
| US-20180354953-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | EGFR, ERBB2, ERBB4 | ATP6V1B1 2123/4885PDGFRB 27/4885PDGFRA 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.